Startup | September 29, 2021
Digital health-start-up MFine raises US $ 48 million
Since its inception, over three million users have used MFine services with the platform clocking over three lakh monthly transactions
Since its inception, over three million users have used MFine services with the platform clocking over three lakh monthly transactions
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
The CAC solution cleared by the U.S. FDA analyses already existing non-gated CT scans and quantifies the coronary artery calcium in order to identify, stratify, and facilitate treatment pathways for patients with cardiovascular disease
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Subscribe To Our Newsletter & Stay Updated
